Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 69

Results For "BSE"

973 News Found

Aster Pharmacy forays into Bangladesh
Healthcare | September 22, 2022

Aster Pharmacy forays into Bangladesh

Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.


Dolomite Bio launches an affordable microfluidic system for custom protocol development
News | September 21, 2022

Dolomite Bio launches an affordable microfluidic system for custom protocol development

Dolomite Bio scientist demonstrating pipetting into the Nadia Go


Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Biotech | September 15, 2022

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.


AstraZeneca launches up-skilling program iPHARMACY
News | September 15, 2022

AstraZeneca launches up-skilling program iPHARMACY

The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala


We will vaccinate 100% of the animals by 2025: Narendra Modi
Policy | September 13, 2022

We will vaccinate 100% of the animals by 2025: Narendra Modi

The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals


Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India
News | September 12, 2022

Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India

Pfizer’s Paxlovid is approved by US FDA for COVID treatment


Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
Clinical Trials | September 10, 2022

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients


Panacea Biotec received US FDA communication for Baddi facility
Drug Approval | September 09, 2022

Panacea Biotec received US FDA communication for Baddi facility

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved


Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital
News | September 07, 2022

Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital

In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery